Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 198,812
  • Shares Outstanding, K 246,237
  • Annual Sales, $ 1,200 K
  • Annual Income, $ -177,120 K
  • EBIT $ -211 M
  • EBITDA $ -209 M
  • 60-Month Beta 1.24
  • Price/Sales 180.16
  • Price/Cash Flow N/A
  • Price/Book 1.22
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.75
  • Most Recent Earnings $-0.18 on 11/12/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 287.41% ( +107.71%)
  • Historical Volatility 150.46%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 287.41% on 11/21/24
  • IV Low 18.27% on 01/11/24
  • Put/Call Vol Ratio 0.15
  • Today's Volume 348
  • Volume Avg (30-Day) 1,876
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 19,816
  • Open Int (30-Day) 28,851

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.13
  • Number of Estimates 4
  • High Estimate -0.07
  • Low Estimate -0.16
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +35.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7633 +4.23%
on 11/21/24
2.0800 -61.75%
on 10/30/24
-1.1544 (-59.20%)
since 10/21/24
3-Month
0.7633 +4.23%
on 11/21/24
2.1750 -63.42%
on 10/18/24
-1.1144 (-58.35%)
since 08/21/24
52-Week
0.7633 +4.23%
on 11/21/24
3.7300 -78.67%
on 02/16/24
-0.2844 (-26.33%)
since 11/21/23

Most Recent Stories

More News
Ivan H. Cheung Elected to Board of Directors of Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals announces Ivan H. Cheung’s election to its Board of Directors, highlighting his extensive biopharmaceutical experience.Quiver AI SummaryLexicon Pharmaceuticals, Inc. has announced...

LXRX : 0.8022 (-0.64%)
Lexicon Appoints Ivan H. Cheung to Board of Directors

LXRX : 0.8022 (-0.64%)
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago

LXRX : 0.8022 (-0.64%)
Lexicon: Q3 Earnings Snapshot

Lexicon: Q3 Earnings Snapshot

LXRX : 0.8022 (-0.64%)
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

LXRX : 0.8022 (-0.64%)
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

LXRX : 0.8022 (-0.64%)
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

LXRX : 0.8022 (-0.64%)
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

LXRX : 0.8022 (-0.64%)
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

LXRX : 0.8022 (-0.64%)
Lexicon Announces Outcome of FDA Advisory Committee for Zynquistaâ„¢ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

LXRX : 0.8022 (-0.64%)

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 0.9710
2nd Resistance Point 0.9330
1st Resistance Point 0.8702
Last Price 0.8022
1st Support Level 0.7694
2nd Support Level 0.7314
3rd Support Level 0.6686

See More

52-Week High 3.7300
Fibonacci 61.8% 2.5967
Fibonacci 50% 2.2466
Fibonacci 38.2% 1.8966
Last Price 0.8022
52-Week Low 0.7633

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar